Drug profile · INN
amivantamab and hyaluronidase-lpuj
RYBREVANT FASPRO
amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
Drug details — amivantamab and hyaluronidase-lpuj
- US status
- approved
- Class
- —
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is amivantamab and hyaluronidase-lpuj?
amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for amivantamab and hyaluronidase-lpuj?
RYBREVANT FASPRO is a marketed brand name for amivantamab and hyaluronidase-lpuj. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amivantamab and hyaluronidase-lpuj?
amivantamab and hyaluronidase-lpuj has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.